NEW YORK (GenomeWeb News) – Vermillion said today that it has obtained permits and completed regulatory processes required for opening a clinical reference laboratory.

In a filing with the US Securities and Exchange Commission, the company said that the lab, Aspira Labs, "will offer tests related to gynecologic oncology and women’s health," including its OVA1 ovarian cancer test.

The lab will be led by Herbert Fritsche, formerly clinical chemistry section chief in the Department of Pathology and Laboratory Medicine at MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.